
|Articles|February 18, 2013
Dispute Develops Over Discount Drug Program
Advertisement
When a private oncology practice in Memphis formed a partnership with a nearby hospital in late 2011, the organizations proclaimed that the deal would “transform cancer care” in the region.
What they did not emphasize was that the deal would also create a windfall for them worth millions of dollars a year, courtesy of an obscure federally mandated drug discount program.
Read the full story:
Source: The New York Times
Advertisement
Related Content
Advertisement


MRI Shows Hypothalamic Atrophy in Narcolepsy Type 1, Sparing Subregion
Published: | Updated:



Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Tirzepatide Label to Reduce Cardiovascular Risk in Type 2 Diabetes
2
Unvaccinated COVID-19 Infection Tied to Higher Myocarditis Risk
3
Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug
4
As GLP-1 Costs Climb, Medicare Part D Plans Face a Reckoning
5
